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Treatment of muscle-invasive bladder cancer remains a major clinical challenge. Aberrant
HGF/c-MET upregulation and activation is frequently observed in bladder cancer correlating
with cancer progression and invasion. However, the mechanisms underlying HGF/c-MET-
mediated invasion in bladder cancer remains unknown. As part of a negative feedback loop
SMAD7 binds to SMURF2 targeting the TGFβ receptor for degradation. Under these condi-
tions, SMAD7 acts as a SMURF2 agonist by disrupting the intramolecular interactions within
SMURF2. We demonstrate that HGF stimulates TGFβ signalling through c-SRC-mediated
phosphorylation of SMURF2 resulting in loss of SMAD7 binding and enhanced SMURF2
C2-HECT interaction, inhibiting SMURF2 and enhancing TGFβ receptor stabilisation. This
upregulation of the TGFβ pathway by HGF leads to TGFβ-mediated EMT and invasion. In vivo
we show that TGFβ receptor inhibition prevents bladder cancer invasion. Furthermore,
we make a rationale for the use of combinatorial TGFβ and MEK inhibitors for treatment of
high-grade non-muscle-invasive bladder cancers.
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B ladder cancer is a highly prevalent disease ranking eleventhmost common cause of cancer-related deaths worldwide1.Initial tumourigenesis originates within the urothelium
layer lining the inner surface of the bladder with more-
progressive tumours invading the surrounding muscularis pro-
pia eventually leading to metastatic disease. Approximately 75%
of bladder cancers initially present as non-muscle-invasive blad-
der cancer (NMIBC). Diagnosis and primary clinical manage-
ment is achieved by transurethral resection of the bladder tumour
(TURBT) possibly followed by intravesical immunotherapies,
primarily bacillus Calmette-Guérin (BCG)2–4. However, super-
ficial bladder tumours have a high recurrence rate and patients
require intensive costly management. The remaining 25% of
bladder cancers are muscle-invasive bladder cancers (MIBC). For
those patients progressing on intravesical treatments or patients
presenting MIBC the standard of care remains cystectomy with or
without chemotherapy5.
Epithelial–mesenchymal transition (EMT) is a multistep pro-
cess that was first recognised as a critical event in the shaping of
embryos during gastrulation and subsequently during
organogenesis6,7. Indeed, the significant parallels in cell plasticity
between embryonic development and carcinoma progression has
led to the idea of EMT as a central driver of epithelial-derived
tumour malignancies8. Furthermore, the transition from an epi-
thelial state toward a more mesenchymal-like state has been seen
as a fundamental requirement for cellular invasion and
metastasis7,9–11. The observation that EMT occurs at the invasive
front of the primary tumour has advocated the role of micro-
environment signals generated by the surrounding stromal cells
as inducers of EMT12–14. These signals consist of an array of
cytokines and growth factors including hepatocyte growth factor
(HGF), epidermal growth factor (EGF), transforming growth
factor-β (TGFβ) and insulin-like growth factor-1 (IGF-1)15. HGF
has been found to be significantly elevated in the serum and urine
of patients with MIBC and its expression is correlated with poorer
overall survival16,17. Furthermore, elevated expression levels of
activated c-Met receptors identified in MIBC enhances the
invasive and metastatic potential of bladder carcinoma cells18–22.
The canonical TGFβ receptor (TβR) pathway has also been
demonstrated to be a critical regulator of EMT, invasion and
metastasis23–26. TGFβ ligand activation of the pathway is con-
ducted through the type II (TβRII) and type I (TβRI) receptors.
Upon activation of the receptors, intracellular signalling is initi-
ated through the phosphorylation of receptor SMADs (SMAD2/
SMAD3) permitting oligomerization with the co-SMAD,
SMAD427. Upon entry into the nucleus the R-SMAD/SMAD4
transcription factor complex regulates the expression of hundreds
of genes, including a number of transcription factors critical for
EMT23. To ensure external cues generate desired intercellular
responses, a number of inhibitory feedback loops exist to limit
unwanted hyperactivation of the pathway. For TβR signalling,
SMAD7, a transcriptional target of the SMAD complexes,
acts as scaffold to recruit the E3 ligase SMURF2 to the TβR
complex to facilitate receptor degradation and attenuate TGFβ
signalling28–31. Furthermore, SMAD7 can also function as an
agonist for SMURF2 activity. To limit unwanted activity toward
its substrates the N-terminal C2 domain of SMURF2 interacts
with its C-terminal HECT domain, inhibiting ubiquitin thioester
formation of its catalytic cysteine residue. The binding of SMAD7
to the WW3 domain of SMURF2 abrogates the inhibitory
intramolecular interactions between the C2 and HECT domains,
facilitating SMURF2 ubiquitin ligase activity32.
The elevated levels of HGF in patients with MIBC compared
with patients with superficial bladder cancer suggests that HGF
has a role in inducing EMT and invasion in bladder cancer
progression18,20. We and others have previously reported on the
role of HGF in EMT induction33,34. However, the precise
mechanism through which c-MET activation induces EMT
remains undetermined. Here we elucidate the mechanism
through which activated c-Met promotes downstream TβR sig-
nalling enhancing EMT and invasion in vitro, and tumour pro-
gression in bladder carcinoma orthotopic transplantation model.
Results
HGF/c-Met confers invasive properties to bladder carcinoma
cells. To identify the mechanisms through which HGF and its
cognate receptor, c-MET, induces EMT in bladder cancer we
treated the rat bladder carcinoma cell line NBT-II, with either
HGF or EGF and analysed changes in cellular morphology with
EMT marker expression (Fig. 1a, Supplementary Fig. 1a). HGF
and EGF treatment decreased intercellular adhesion as exhibited
by loss of desmosomes and E-cadherin junctional complexes
while increasing vimentin expression15,33–36. NBT-II cell motility
was assessed using time-lapse microscopy (Supplementary
Fig. 1b). Treated NBT-II cells travelled further while displaying
an increase in velocity compared with control cells (Supple-
mentary Fig. 1c, d). To investigate the phenotypic changes fol-
lowing HGF exposure, images of NBT-II cells were taken at 5 min
intervals for 48 h (Fig. 1a). Following HGF treatment, coherent
sheets of epithelial NBT-II carcinoma cells progressively dis-
sociated over time, leading to establishment of single
mesenchymal-like migratory cells as early as 9 h (Fig. 1a). Fur-
thermore, tracking of cells at early time points showed that NBT-
II cells engaged into locomotion within 2–4 h following HGF
induction (Fig. 1b, c). HGF-treated cells decreased E-cadherin
expression, dissociated from one another and exhibited an
increase in vimentin (Fig. 1d). These effects were annulled upon
treatment with the c-MET inhibitor JNJ38877605 (Supplemen-
tary Fig. 1e). Collectively, these results indicate that HGF induces
a rapid EMT response in NBT-II cells.
c-Met activation drives TβR-dependent SMAD2 phosphoryla-
tion. To understand the intracellular responses upon HGF
treatment, we probed a phospho-specific antibody microarray
with lysates from control or HGF-treated NBT-II cells 2 h post
treatment (Fig. 2a, Supplementary Data 1). Intriguingly, HGF
upregulated the phosphorylation of R-SMADs at both the linker
residues (Ser204; pSMAD2L) and at the C-terminal motif
(Ser467; pSMAD2C). pERK levels were also unexpectedly
reduced37. Notably, SMAD2 C-terminal phosphorylation can
only occur through TGFβR activation, revealing a potential cross-
activation of the TβR receptors by HGF38. This was validated as
both pSMAD2L and pSMAD2C correspondingly increased in a
HGF dose-dependent manner (Fig. 2b, Supplementary Fig. 2a).
NBT-II cells treated with HGF in a time-dependent manner
demonstrated a rapid induction of pERK at 5 mins with an
analogous increase phospho-SMAD2L (Fig. 2c, Supplementary
Fig. 2b)39. Notably, ERK phosphorylation diminished at later
time points, a result in line with our phosphoprotein array.
Importantly, SMAD2C phosphorylation was upregulated only 1 h
after HGF induction (Fig. 2c, Supplementary Fig. 2b). Also c-SRC
activation occurred at 15 mins after HGF treatment and corre-
sponded with downregulation of pERK and upregulation of
pSMAD2C (Fig. 2c, Supplementary Fig. 2b). Co-treatment with
the c-Met inhibitor JNJ38877605 blocked HGF activation of both
the phosphorylated isoforms of SMAD2 indicating that HGF-
mediated phosphorylation of SMAD2 is dependent upon active c-
Met signalling (Fig. 2d). Next, we sought to determine whether
HGF-induced pSMAD2C was directly dependent upon TβR
activity. To this end, we performed a nuclear cytoplasmic frac-
tionation assay to identify the localisation of pSMAD2 in the
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absence and presence of the TβR inhibitor A83-0140. HGF
treatment enhanced nuclear pSMAD2 localisation, an effect that
was partially reversed upon the co-addition of A83-01 (Fig. 2e, f).
Furthermore, NBT-II cells expressing a kinase-inactive TβRI
resulted in the cytoplasmic retention of SMAD2 following HGF
exposure, indicating that TβR activation is required for HGF-
induced pSMAD2C (Fig. 2g). Next, we sought to investigate the
impact of SMAD2 on HGF-induced EMT. siRNA-mediated
knockdown of SMAD2 prevented the dispersion of HGF-treated
cell colonies (Supplementary Fig. 2c, d). As the Activin receptors
(ACVR2B and ALK4) have previously been shown to play a role
in the induction of SMAD2 we utilised soluble Activin receptor
type 2B-Fc ligand traps or pan TGFβ-neutralising antibodies to
observe if ALK4 or ALK5 is involved in HGF-induced
pSMAD2C. While Activin inhibition minimally decreased
pSMAD2C levels, neutralising TGFβ completely abolished HGF-
mediated pSMAD2C (Supplementary Fig. 2e). Similar observa-
tions were made with catalytically inactive mutants of ALK4 and
ALK5 (Supplementary Fig. 2f). Co-treatment with A83-01 pre-
vented HGF-induced EMT as observed by the reconstitution of
desmosomes and the concomitant loss of the mesenchymal
marker vimentin (Supplementary Fig. 3a). In addition, HGF-
induced migration was attenuated upon treatment with A83-01
(Supplementary Fig. 3b, c). These results confirm the role of the
canonical TβR pathway in HGF-induced EMT and motility.
Next, we analysed the RNA expression profiles of NBT-II cells
following HGF treatment at 2, 4, 6, 9, 24 and 48 h. We noted an
early upregulation of 229 genes 2 h post HGF treatment, the
majority of which remained upregulated up to 9 h post treatment
(Supplementary Fig. 4a). Interestingly, a number of described
TGFβ-regulated genes were upregulated by HGF as early as 2 h,
indicating that transcription of these genes may be TGFβ
pathway-dependent (Supplementary Fig. 4b). Indeed, analysis of
a TβR/BMPR signalling pathway profiler qRT-PCR array
indicated that HGF induced the expression of 28 TβR target
genes (Supplementary Fig. 4c, Supplementary Data 2). To explore
the functional processes of these 229 early transcribed genes, we
performed pathway enrichment analysis using Enrichr41. TGFβ
signalling showed the two highest combined enrichment scores
with six different TβR signalling gene sets, demonstrating
significance (Fig. 2h, Supplementary Data 3). Furthermore,
comparison of our transcriptional signature in NBT-II cells
following HGF treatment indicated a significant enrichment score
to either MSigdb v5.0 Hallmark TGFβ or EMT signatures
(Supplementary Fig. 4d). To further confirm the role of the TGFβ
pathway in our observations we analysed the effect of A83-01 on
HGF-induced transcription. Co-treatment with A83-01 reversed
gene expression of a subset of genes associated with TGFβ
signalling as determined by Enrichr (Supplementary Fig. 4e). In
particular, A83-01 diminished HGF-induced PAI-1 mRNA and
protein levels (Supplementary Fig. 4f, g). Taken together, these
results suggest that HGF induces an early TβR expression
signature required for EMT in bladder cancer.
HGF/c-MET driven c-SRC inhibition of SMURF2 ligase
activity. To uncover novel repressors of EGF, HGF and IGF-
induced EMT we previously performed a high content screening
assay where we identified compounds targeting c-SRC as an
antagonist of this process34. Follow-up analyses demonstrates a
near-complete inhibition of cell scattering when cells were treated
with the c-SRC inhibitor AZD0530 and HGF compared with
HGF alone (Fig. 3a). Furthermore, co-treatment with AZD0530
blocked HGF, EGF, or IGF-induced EMT as observed by the
reconstitution of desmosomes and the concomitant loss of
vimentin (Supplementary Fig. 5a, b). Correspondingly, co-
transfection of NBT-II cells with siRNA targeting c-SRC
enhanced the presence of E-cadherin at cell–cell junctions and
decreased vimentin expression compared with cells treated with
HGF alone (Supplementary Fig. 5c, d).
Next, we sought to analyse the intercellular responses in NBT-
II cells upon treatment with the SRC inhibitors AZD0530 and
PP1. Treatment with either inhibitor resulted in a similar protein
expression pattern to TβR downregulation with TβR inhibitors
A83-01 and LY2157299, displaying comparable decreases in
pSMAD2C and upregulation of pERK (Fig. 3b). c-SRC is
frequently activated in human cancer and has been shown to
play a role in EMT, resulting in tumour invasion and metastasis,
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Fig. 1 HGF-induced EMT in NBT-II carcinoma cells. a Phase contrast images
of NBT-II cells at 0, 2, 4, 6, 9 and 24 h post HGF induction. Scale bars: 50
μm. b Cell tracks of NBT-II cells at 0, 2, 4, 6, 9 and 24 h post HGF induction.
Data shown are representative of three independent and reproducible
experiments. c Bar charts display velocity (left panel), total distance
(middle panel) and displacement (right panel) of NBT-II cells over 24 h.
Bars represent mean ± SD of three independent experiments. A two-tailed
Student’s t test compares the treated versus untreated cell populations,
***P < 0.001. d Representative immunofluorescence images of NBT-II
stained with E-cadherin and Vimentin at 0, 4 and 24 h post HGF. Scale
bars: 50 μm
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but no evidence has directly demonstrated a mechanism
describing c-SRC regulation of pSMAD242–45.
Both SMURF2 and its orthologue NEDD4 harbour a C2 and
HECT domain whereby the C2 domain binds to the HECT
domain, resulting in a closed conformation of the protein, and
loss of enzymatic activity32. Recently, it has been demonstrated
that c-SRC phosphorylates a number of tyrosine residues on
NEDD4, disrupting the C2-HECT complex, leading to catalytic
activation of ligase46. Similarly, the binding of SMAD7 to
SMURF2 antagonises C2-HECT interaction permitting activation
of SMURF2, leading to eventual degradation of the TβR complex
and loss of TβR signalling32. Although, the phosphorylation of
NEDD4 by c-SRC resulted in the activation of NEDD4, a
mechanism counter-intuitive to our proposed observations, we
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investigated whether c-SRC could form a complex with SMURF2.
Indeed, c-SRC bound to SMURF2 under both ectopically
expressed and physiological conditions (Fig. 3c, Supplementary
Fig. 5e, f). Furthermore, HGF treatment enhanced the binding of
c-SRC to SMURF2 (Fig. 3d). Next, we tested if c-SRC or other
SRC family members phosphorylated SMURF2. Both c-SRC and
LCK enhanced tyrosine phosphorylation of SMURF2 but not
LYN, FYN, or YES (Fig. 3e). Moreover, overexpression of a
constitutively active mutant of c-SRC (Y530F) enhanced tyrosine
phosphorylation compared with its wild-type counterpart (Sup-
plementary Fig. 5g). In contrast, co-transfection with either
kinase-dead or inactive mutants of c-SRC (K298M and Y419F) or
the addition of the SRC inhibitors PP2 and Dasatinib inhibited
SMURF2 tyrosine phosphorylation (Fig. 3f, Supplementary
Fig. 5g).
To identify the putative phosphorylation sites on SMURF2
regulated by c-SRC, we immunoprecipitated SMURF2 from
SILAC (Stable Isotope Labelling with Amino Acids in Cell
Culture)-labelled HEK293T cells in the absence or presence of c-
SRC followed by quantitative mass spectrometry analysis. We
identified five residues, which are phosphorylated (Ser44, Thr249,
Tyr314, Ser384 and Thr466) on SMURF2. However, only Tyr314
phosphorylation was identified with SILAC ratios clearly different
from the ~ 1:1 ratios observed in unmodified SMURF2 protein
and the other candidate residues (Fig. 3g, Supplementary Fig. 6a,
b). Analysis of SMURF2 phosphorylation by c-SRC, utilising a
SMURF2 mutant harbouring a phenylalanine mutation at
Tyr314 significantly reduced tyrosine phosphorylation of
SMURF2 (Fig. 3h). However, low levels of SMURF2 tyrosine
phosphorylation were still detected, indicating other sites on
SMURF2 may be phosphorylated by c-SRC. As NEDD4 is
phosphorylated by c-SRC at a number of different residues
(Tyr43, Tyr365, Tyr366 and Tyr585) we performed sequence
alignment with NEDD4 and SMURF2 and identified Tyr434,
corresponding to Tyr585 in NEDD4, as a candidate phosphor-
ylation site for c-SRC (Fig. 3g)46. Generation of a double
phenylalanine mutant at Tyr314 and Tyr434 (henceforth referred
to as FF) completely inhibited c-SRC-mediated phosphorylation
of SMURF2 (Fig. 3h). To further confirm the phosphorylation of
SMURF2 by c-SRC, we generated phospho-specific antibodies
targeting both loci. In Fig. 3i, j c-SRC enhanced phosphorylation
of Tyr314 and Tyr434, an effect, which was abrogated in the
corresponding SMURF2-phenylalanine-mutants.
SMURF2 is a negative regulator of TGFβ activity. Therefore, to
determine whether these residues are critical for SMURF2-
mediated function, we co-transfected a TGFβ-responsive lucifer-
ase reporter (CAGA-Luc) with either wild-type SMURF2 or the
SMURF2 (FF) mutant. As expected, ectopic expression of
SMURF2 and the SMURF2 (FF) mutant significantly down-
regulated CAGA-Luc activity (Fig. 3k). In contrast, ectopic
expression of either SMURF2 phospho-mimetic mutants
SMURF2 (Y314E) or SMURF2 (Y434E) partially inhibited the
ability of SMURF2 to downregulate the reporter (Fig. 3l).
However, transfection of a SMURF2 mutant with glutamic
residues at both tyrosine residues (Y314E/Y434E, referred to as
EE) completely abrogated SMURF2-mediated downregulation of
luciferase activity (Fig. 3l). Collectively, these results indicate that
the tyrosine kinase c-SRC phosphorylates SMURF2 at Tyr314 and
Tyr434 blocking SMURF2-mediated downregulation of the
canonical TGFβ pathway.
Phosphorylation of Tyr314 and Tyr434 by c-SRC inhibits
SMAD7 binding and enhances C2-HECT domain interaction.
As c-SRC phosphorylation of NEDD4 led to enhanced activity,
we sought to understand what effect c-SRC phosphorylation has
on SMURF2. Ectopic expression of c-SRC completely abolished
SMURF2 auto-ubiquitination, a mark of SMURF2 ligase activity
(Fig. 4a). In addition to the C2 and HECT domains, SMURF2
contains three WW domains, which recognise PPXY (PY) motifs
on SMURF2 target proteins or adapters, such as SMAD7. Further
investigations have shown that the PY motif of SMAD7 directly
interacts with the WW3 (297–330aa) domain of SMURF247,48. As
c-SRC phosphorylates SMURF2 at Tyr314 in the WW3 domain,
we sought to explore if phosphorylation of Tyr314 altered
SMAD7 binding. The structure of WW3 domain of SMURF2
complexed with a SMAD7 peptide incorporating the PY motif
(PDB ID: 2LTZ) provides a model to investigate this effect. We
generated an electrostatic potential surface of WW3 domain,
which, reveals that the PY motif of SMAD7 tracks along a
hydrophobic region of the domain, where Tyr314 resides
(Fig. 4b). We subjected this complex structure to two indepen-
dent molecular dynamics simulations differing in the chemical
state of Tyr314. Our simulations reveal that upon Tyr314 phos-
phorylation, SMAD7 peptide is no longer able to form a complex
with the WW3 domain (Fig. 4b–d). The addition of the negative
charge through phosphorylation at Tyr314 attracts the adjacent
arginine residues R306 and R321, forming a salt-bridge interac-
tion collectively altering the chemical and physical nature of the
binding interface in the WW3 domain, resulting in the preven-
tion of SMAD7 binding (Fig.4c, d). Indeed, co-
immunoprecipitation of SMAD7 with SMURF2 was diminished
in SMURF2 (Y314E) mutants, mimicking c-SRC phosphorylation
(Fig. 4e). Analogously, co-expression of c-SRC decreased the
binding of SMAD7 to SMURF2 and to the SMURF2 catalytically
inactive mutant (SMURF2 C/A), but not with the SMURF2 iso-
forms Y314F and Y434F (Fig. 4f, g). These results indicate that
phosphorylation of Tyr314 within the WW3 domain of SMURF2
inhibits the binding of SMAD7 to SMURF2.
As indicated, c-SRC phosphorylation of NEDD4 at Tyr585
disrupts the C2-HECT domain interaction, resulting in catalytic
activation. To understand the role of the matching Tyr434
Fig. 2 c-Met and TGFβ signalling in HGF-mediated EMT of NBT-II carcinoma cells. a Bar graph displays ratio of phosphorylated proteins at 2 h post HGF
compared with control. b Western blot analysis of NBT-II cells treated with escalating doses of HGF at various concentrations for 2 h. Lysates are probed
with indicated antibodies. c Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF. Lysates were collected at denoted time points and probed
with indicated antibodies. dWestern blot analysis of NBT-II cells treated with 5 ng/ml of HGF in the absence or presence of c-MET inhibitor JNJ38877605.
Lysates were collected at denoted time points and probed with indicated antibodies. e Western blot analysis of nuclear (n) and cytoplasmic (c) fractions
isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Lysates were collected at denoted time points and probed
with indicated antibodies. f Bar chart displays ratio of pSMAD2 band intensity in nuclear (n) fractions compared with total SMAD2 (nuclear+ cytoplasmic)
fractions isolated from NBT-II cells treated with HGF for 2 h with or without TβRI inhibitor (A83-01, 8 μM). Bars represent mean ± SD of three independent
experiments. A two-tailed Student’s t test compares the treated cell populations, **P < 0.01, ***P < 0.001. g Immunofluorescence images of SMAD2-
stained cells transfected with either control vector or TβRI-dominant negative (DN) mutant construct with or without HGF. Scale bars: 10 μm. h Scatter plot
of 245 pathways combined enrichment score (x axis) and p value in −log10 scale (y axis) from Enrichr. Pathways related to TGFβ are denoted in red.
Dotted line indicates p= 0.05. The adjusted p value is the Benjamini–Hochberg corrected p value from hypergeometric test
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phosphorylation site in SMURF2, we modelled the complex state
structure of C2-HECT domains (Fig. 5a) (See methods section for
description of model generation; Supplementary Fig. 7a–e).
Although, Tyr434 does not directly overlap with the C2 domain,
we observed that a highly charged segment within the C2 domain
formed by residues 82HKKIHKK88 is located in proximity to
Tyr434 (Fig. 5a, b). In an unphosphorylated state, Tyr434 does
not form any significant interaction with this motif. However, in
contrast to NEDD4, tyrosine phosphorylation at Tyr434 enhances
the binding between C2 and HECT domains. We observe that
phosphorylation at Tyr434 changes the local electrostatic
potential of the HECT domain region from one which is
relatively positive towards one being more negative (Fig. 5b, c).
This generates a favourable environment for the positively
charged motif of C2 to come into closer contact with the newly
formed negatively charged region, surrounding Tyr434
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permitting a stronger interaction between Lys87 and phosphory-
lated Tyr434 (Fig. 5d). The other basic residues, H86 and K88,
embedded in the motif, though not as close to Y434 as compared
with K87 may still form a favourable interaction as electrostatic
interactions have significant long-range effects. This favourable
interaction between the phosphotyrosine and lysine/histidine
residues could be an important factor in the enhancement of the
binding between C2 and HECT domains of SMURF2 in the
phosphorylated state of Tyr434. Thus, the proposed structural
model of the C2-HECT complex suggests a favourable interaction
between the phosphotyrosine and lysine/histidine residues, which
could be an important factor in the enhancement of the binding
between C2 and HECT domains of SMURF2 when Tyr434 is
phosphorylated. However, this may not be the only optimum
binding geometry and there could be other similar modes of
interactions between the two domains in the ensemble of
structures.
Our results indicate that c-SRC phosphorylation of SMURF2 at
Tyr314/Tyr434 prompts C2-HECT domain interaction, main-
taining SMURF2 in a closed inactive conformation. Accordingly,
auto-ubiquitination of SMURF2 was diminished by both Y314E
and Y434E mutations (Fig. 5e). In contrast, SMURF2 Y434F
showed a similar demonstrable increase in incorporated ubiquitin
levels compared with the SMURF2 FF29/30AA, a mutant that
inhibits the binding between the C2/HECT domains rendering
SMURF2 catalytically active (Fig. 5f)32. Furthermore, mutation of
Tyr314 and Tyr434 to phenylalanine completely annulled the
ability of c-SRC to downregulate SMURF2 activity (Fig. 5g).
Collectively our studies reveal a mechanism in which HGF-
induced c-SRC phosphorylation of SMURF2 at Tyr314 and
Tyr434 functions to negatively regulate E3 ligase activity by
maintaining complex formation between the C2 and HECT
domains.
HGF/c-MET utilise c-SRC/SMURF2 axis as a bimodal switch to
regulate TGFβ and MAPK kinase signalling. SMURF2 can
function as both a tumour suppressor or an oncogene30. Recently,
it has been shown that SMURF2 ubiquitinates and degrades the
E3 ligase β-TrCP, resulting in the stabilisation of K-RAS49. As
ERK phosphorylation was rapidly downregulated at 2 h post HGF
treatment, we hypothesised that c-SRC-mediated inhibition of
SMURF2 through phosphorylation at Tyr314 and Tyr434 may act
as a negative feedback loop to limit MAPK hyperactivation. In
contrast, loss of HGF-mediated c-SRC phosphorylation would
lead to SMURF2 activation and a decrease in TβR stability and
overall downregulation of TGFβ signalling. As expected, HGF
addition enhanced membrane localisation of TβRI (Fig. 6a).
Moreover, HGF-induced TβR stability was significantly decreased
in cells treated with the c-SRC inhibitor AZD0530 (Fig. 6b,
Supplementary Fig. 7f–h). Next, we analysed the effect of
SMURF2 or the relevant SMURF2 mutants on TβRI stability. Co-
transfection of wild-type SMURF2 or SMURF2(FF) decreased
TβRI levels (Fig. 6c). In contrast, ectopic expression of SMURF2
(EE) completely diminished the ability of SMURF2 to degrade
TβRI (Fig. 6c). In addition, ectopic expression of c-SRC stabilised
TβRI in both the presence and absence of SMURF2 (Fig. 6d). The
ability of SMURF2 and SMURF2(FF) to downregulate TβRI
stability was blocked by the addition of the proteasome inhibitor,
MG132, indicating that tyrosine phosphorylation of SMURF2
blocks SMURF2 downregulation of TβR potentially enhancing
pSMAD2 signalling (Fig. 6e). Indeed, both SMURF2 and
SMURF2(FF) repressed SMAD2 phosphorylation, but not the
SMURF2(EE) mutant (Fig. 6f).
Next, we evaluated the consequence of SMURF2 phosphoryla-
tion on MAPK activation. As expected, expression of SMURF2 or
SMURF(FF) decreased β-TrCP levels (Fig. 6g)49. Furthermore,
and in complete contrast to TβR signalling, both SMURF2 and
SMURF2(FF) enhanced MAPK activation whereas SMURF2(EE)
abrogated downstream MAPK activation (Fig. 6h). Collectively,
these results suggest that SMURF2 acts as a bio-modal switch
between MAPK and TGFβ activation and suppression, an effect
regulated by HGF-induced c-SRC activation (Fig. 6i).
TβR suppression inhibits HGF-induced EMT and invasion. c-
Met expression level correlates with tumour grade and poor
prognosis in human bladder cancer patients18–20. To further
investigate the potential role of the HGF/c-Met axis and EMT in
bladder cancer we probed the TCGA Bladder Cancer data set
(BLCA n= 408) against our established EMT signature50. A high
EMT score indicates a sample, portends toward a more
mesenchymal-like phenotype, and vice versa. Importantly, HGF,
c-Met and p-c-Met expression all correlated with the EMT sig-
nature (Fig. 7a). Furthermore, stratification of bladder cancer
patients into two groups based on the HGF expression deter-
mined that patients with high HGF expression had significantly
reduced overall survival (Fig. 7b).
Recently, we performed a meta-analyses of 2411 patients from
19 bladder cancer cohorts and identified six major molecular
subtypes, including two predominant subtypes denoted as
Mesenchymal-like (MES) and Squamous-cell carcinoma-like
(SCC)51. Cross analysis of the subtypes with our established
EMT signature indicated that both MES and SCC subtypes had a
more pronounced EMT signature compared with other subtypes.
Importantly, there was a significant subtype association with SCC
Fig. 3 c-SRC phosphorylates SMURF2 at Tyr314 and Tyr434. a Cell tracks of HGF-treated NBT-II cells at 24 h in presence or absence of the c-SRC inhibitor
AZD0530 (1 μM). b Western blot analysis of NBT-II cells treated with 5 ng/ml of HGF and A83-01 (8 μM), or LY2157299 (1 μM), PD0325901 (1 μM),
MEK162 (1 μM), AZD0530 (1 μM), or PP1 (1 μM). Lysates were collected at 90min post HGF treatment and probed with indicated antibodies. c 293 T cells
were transfected as indicated. Lysates were immunoprecipitated with anti-MYC. Whole cell extracts were probed with the indicated antibodies. d 293
T cells treated with HGF for indicated time points. Lysates were immunoprecipitated with anti-SMURF2. Whole cell extracts were probed with indicated
antibodies. * indicates IgG band. e 293 T cells were transfected as indicated. Lysates were immunoprecipitated with anti-MYC affinity resin. Whole cell
extracts were probed with the indicated antibodies. pY signifies tyrosine phosphorylation. f 293 T cells were transfected as indicated. After 24 h cells were
treated with c-SRC inhibitors PP2 (1 μM) or dasatinib (1 μM). Twenty-four hours later, cells were lysed and immunoprecipitated with anti-MYC. Whole-cell
extracts were probed with the indicated antibodies. g Schematic of c-SRC tyrosine phosphorylation sites on SMURF2. Red denotes identification by mass
spectrometry. Green denotes identification through sequence alignment. h 293 T cells were transfected as indicated. After 48 h, cells were lysed and
immunoprecipitated with anti-MYC. Whole-cell extracts were probed with the indicated antibodies. i 293 T cells were transfected as indicated. Whole-cell
extracts were probed with the indicated antibodies. j 293 T cells were transfected as indicated. Whole-cell extracts were probed with the indicated
antibodies. k 293 T cells were co-transfected with a CAGA-luciferase reporter and either SMURF2 WT, or SMURF2 (FF). Cells were stimulated with TGF-β
overnight and luciferase activity was measured. l 293 T cells were co-transfected with a CAGA-luciferase reporter, SV40-Renilla and either SMURF2 WT,
or SMURF2 Y314E, Y434E, or the double mutant EE. Cells were stimulated with TGFβ overnight and luciferase activity was measured. For k and l bars
represent mean ± SD of three independent experiments. A two-tailed Student’s t test compares the treated populations, **P < 0.01, ***P < 0.001
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tumours and distant metastasis51. Evaluation of SMURF2, HGF
and c-Met expression in the SCC subtype (n= 272) indicates a
significant correlation with expression and EMT score (SMURF2
R= 0.18, p= 0.003; HGF R= 0.22, p= 0.0003; c-Met R= 0.17,
p= 0.005).
Next, we sought to determine whether p-c-SRC correlated with
pSMAD2C in a collection of bladder cancer patient-derived
samples. Immunohistochemical analysis revealed that p-c-SRC
expression co-expressed with pSMAD2C in all of the histo-
subtypes tested including papillary, urothelial carcinoma with
squamous differentiation and sarcomatoid (Supplementary
Fig. 8a). Furthermore, p-c-SRC expression correlated with nuclear
pSMAD2C in 2/2 papillary urothelial carcinoma and 5/6
urothelial carcinoma with squamous differentiation bladder
carcinoma and neuro-endocrine bladder carcinoma (Supplemen-
tary Fig. 8b, c). This finding confirmed our hypothesis that c-SRC
activity regulates TGFβ activity in bladder cancer.
Next, we probed RNA data sets of bladder cancer cell lines
(n= 21) and scored them against the spectral EMT signature
(Fig. 7c, Supplementary Data 4)50. As certain bladder cancer
subtypes display a mesenchymal phenotype we focused our
attention on cell lines displaying the highest EMT scores to reflect
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what is observed in clinical settings. Importantly, HGF treatment
stimulated c-Met activation in T24, J82 and UMUC3 cell lines an
effect abrogated upon the addition of the c-Met inhibitor
JNJ38877605 (Supplementary Fig. 9a). Moreover, HGF treatment
rapidly induced downstream SMAD2 linker and C-terminal
phosphorylation in T24, J82 and UMUC3 cell lines (Supplemen-
tary Fig. 9b). pSMAD2C phosphorylation was dependent upon c-
SRC activation as treatment with the c-SRC inhibitors AZD0530
and PP1 decreased the phosphorylation levels of SMAD2C
(Supplementary Fig. 9c–e). An increase in the pERK was also
observed upon treatment with AZD0530 (Supplementary
Fig. 9c–e). Furthermore, ectopic expression of SMURF2 or
SMURF2(FF) in UMUC3 cells increased pERK levels, while
SMURF2(EE) enhanced pSMAD2C (Supplementary Fig. 9f).
As HGF leads to TGFβ-mediated EMT in NBT-II cells, we
explored if the TGFβ pathway was essential for tumourigenesis,
EMT and invasion in bladder cancer. To this end, we utilised the
cell lines UMUC3 and T24, the two cell lines which displayed the
highest and lowest levels of activated c-Met, respectively. In both
cell lines HGF exposure enhanced invasion as observed using a
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transwell migration assay an effect diminished upon co-treatment
with JNJ38877605 indicating that HGF-mediated invasion in
UMUC3 and T24 cells is dependent upon active c-Met receptor
signalling (Supplementary Fig. 10a–d). Correspondingly, treatment
of UMUC3 cells with JNJ38877605 limited anchorage-independent
growth (Supplementary Fig. 10e, f). As HGF enhanced invasion in
UMUC3 cells we sought to understand if this function might be
dependent on increased EMT. Indeed, UMUC3 cells treated with
HGF led to a decrease in the epithelial marker E-cadherin, an effect
abolished upon the addition of JNJ38877605 (Supplementary
Fig. 10g). Similarly, treatment with the TβR inhibitor A83-01 in
UMUC3 cells enhanced the levels of cortical actin indicating that
TβR suppression reverts UMUC3 cells to a more epithelial state
(Supplementary Fig. 10h). Taken together, these results suggest
that TGFβ signalling is required for HGF-mediated EMT
induction, and invasion in bladder cancer cell lines.
As, HGF induces c-SRC to phosphorylate and inhibit SMURF2
leading to increased TβR signalling, we transfected UMUC3 and
T24 cells with either WT SMURF2, SMURF2(EE) or SMURF2
(FF) to see if the corresponding c-SRC phosphorylation site
mutants of SMURF2 play a role in HGF-mediated invasion and
EMT. As can be seen in Supplementary Figs. 11A, 10C, SMURF2
(EE) expression enhanced the invasion capacity of both UMUC3
and T24 cells compared with cells expressing WT SMURF2 an
effect further enhanced in cells treated with HGF. In contrast, the
invasion capacity of UMUC3 and T24 cells expressing SMURF2
(FF) was diminished (Supplementary Fig. 11a–d). Furthermore,
ectopic expression of SMURF2(FF) enhanced the levels of β-
catenin at cell–cell contacts while concomitantly decreasing
overall levels of vimentin, indicating that TβR suppression by
SMURF2 leads cells to acquire a more epithelial state (Supple-
mentary Fig. 11e).
Next, we sought to analyse the role of corresponding SMURF2
mutants on targeted inhibition of MAPK and TGFβ pathways. It
would be expected that SMURF2(FF) mutants, which down-
regulates TGFβ signalling but upregulates the MAPK pathway,
would be sensitive to MAPK inhibition. In contrast, SMURF2(EE)
mutants, which downregulates MAPK signalling but upregulates
the TGFβ pathway, would similarly be sensitive to inhibitors that
target the TGFβ pathway. As can be seen in Supplementary
Figs. 12A, B, UMUC3 cells transfected with SMURF2(FF) were
significantly more sensitive to the MEK inhibitor PD0325901 than
WT SMURF2 or untreated SMURF2(FF) expressing cells in
forming colonies under anchorage-independent conditions. More-
over, UMUC3 cells expressing SMURF2(EE) were significantly
more sensitive to TGFβ inhibition with LY2157299 than WT
SMURF2-expressing cells. Interestingly, both SMURF2(FF) and
SMURF2(EE) mutants displayed lower colony formation than WT
SMURF2, indicating that constitutive activation of both TGFβ and
MAPK signalling is required for anchorage-independent growth
(Supplementary Fig. 12a–d). Further analysis of the intercellular
responses indicated that treatment with PD0325901 completely
abolished SMURF2(FF) pERK levels while correspondingly
LY2157299 treatment completely abolished pSMAD2C levels in
SMURF2(EE) cells (Supplementary Fig. 12e, f).
To further investigate if SMAD2C phosphorylation is critical in
bladder tumorigenesis, UMUC3 cells stably expressing SMAD2
WT or a SMAD2 mutant (SMAD2 dnC), containing alanine
residues within the respective C-terminal phosphorylation motif,
were subcutaneously injected into mice. The presence of SMAD2
C-terminal mutations caused an 80% reduction in overall tumour
growth formation thus underscoring the role for TGFβ signalling
in bladder cancer tumourigenesis (Supplementary Fig. 13a–c).
Based on these results we used an orthotopic mouse model of
bladder cancer whereby we could analyze the role of c-MET-
mediated invasion. We choose to utilise UMUC3 cells in this
setting as they expressed the highest levels of activated c-MET.
To detect the growth of UMUC3 tumours in the mouse bladder,
UMUC3 carcinoma cells expressing a mammalian codon-
optimised firefly luciferase2 was generated permitting biolumi-
nescence detection. UMUC3-luc2 cells were inoculated into
trypsin pre-treated bladders of 6–8-week-old mice and the
presence of tumours was confirmed a week later using the
bioluminescence in vivo imaging system. When tumours
reached a bioluminescence intensity of 5e8 photons/sec mice
were paired and treated intraperitoneally with either dimethyl
sulfoxide (DMSO) or A83-01 or LY2157299. Bladder tumours
sporadically shed cells into the urine. Therefore, to analyze the
effect of A83-01 on cellular homoeostasis urine was collected
and placed in cell culture medium. Cells collected from tumour
bearing mice treated with A83-01 clustered together initiating
cell–cell contacts while those from control-treated mice
conferred a similar morphology to parental UMUC3 cell line,
indicating the effective targeting of the tumour with A83-01
(Supplementary Fig. 14a). Notably, TGFβ inhibitor-treated
mice displayed a significant decrease in tumour size (Supple-
mentary Fig. 14b–e). After 2 weeks of treatment, bladders were
collected and H&E staining was performed. Importantly,
tumours isolated from control-treated mice exhibited a near-
complete breakdown of the submucosa layer displaying
characteristics of blood and lymphatic invasion similar to the
phenotype observed in later stage bladder cancers (Fig. 7d, e,
Supplementary Fig. 14f). In contrast, mice treated with either
the TβR inhibitors A83-01 or LY2157299, tumour formation
remained superficial with minimal invasion of the submucosal
layer (Fig. 7d, e, Supplementary Fig. 14f). The overall
percentage of bladder wall invasion in A83-01 or LY2157299
treated mice was 14% and 20.6%, respectively, compared with
89% in control-treated mice. Furthermore, half of control-
treated mice displayed limited but significant lung metastasis
Fig. 5 c-SRC phosphorylation of SMURF2 inhibits SMURF2 ligase activity. a Representative structure from MD simulation of the C2-HECT domain complex.
The HECT domain is shown in electrostatic surface and ribbon representation while the C2 domain is shown in ribbon representation in green colour. The
region that encloses Y434 in HECT and the 82HKKIHKK88 motif in C2 is highlighted within a box (b, c). bMagnified representation of highlighted region in
HECT without the ribbon for clarity. c Representative structure from MD simulation of the phosphorylated Y434, highlighting the equivalent region in
HECT and C2. The electrostatic potential molecular surface shown here (and in Fig. 4b, c) was created using the APBS plugin through the Pymol molecular
visualisation software. A colour gradient from blue to red represents the range of surface potential kT/e values from strongly positive (+3.0) to strongly
negative (−3.0). d Time series plot (in angstrom unit) of the minimum distance between Y434 (OH or P atoms) of HECT and K87 (NZ atom) of C2 in the
Phosphorylated (red colour) and Unphosphorylated (black) state of Y434 during the MD simulation of HECT-C2 complex. e 293 T cells transfected with
wild-type MYC-SMURF2 or indicated SMURF2 mutants and HA-tagged ubiquitin. Following immunoprecipitation of MYC-SMURF2 lysates were resolved
by SDS–PAGE and probed with indicated antibodies. f 293 T cells transfected with WT MYC-SMURF2 or indicated SMURF2 mutants and HA-tagged
ubiquitin. Following immunoprecipitation of MYC-SMURF2 lysates were resolved by SDS–PAGE and probed with indicated antibodies. g 293 T cells
transfected with wild-type MYC-SMURF2 or indicated SMURF2 mutants, HA-tagged ubiquitin and/or Flag-tagged c-SRC. Following immunoprecipitation
of MYC-SMURF2 lysates were resolved by SDS–PAGE and probed with the indicated antibodies
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(four out of eight) while no lung metastasis was detected in TβR
inhibitor-treated mice (Supplementary Fig. 14g–j). Importantly,
however, the remaining tumour maintained a high tumour
proliferation capacity. Taken together, these data indicate that
TβR inhibition induces a change in cell morphology limiting
the invasion capacity, but not the proliferation, of a subpopula-
tion of bladder carcinoma cells.
Combined inhibition of MAPK and TGFβ signalling pathways
suppresses HGF-mediated proliferation and invasion. As
observed, TGFβ inhibition resulted in a significant decrease in
tumour size but did not completely eliminate the tumour,
therefore we hypothesise that TβR inhibition may result in the
loss of negative feedback mechanisms in a subpopulation of the
tumour, resulting in a compensatory activation of MAPK
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Fig. 6 SMURF2 acts as a bimodal switch between TβR and MAPK activation. a NBT-II cells were treated with HGF for indicated time points and
subsequently with biotin for 30mins at 4 °C. Following immunoprecipitation with NeutrAvidin resin lysates were resolved by SDS–PAGE and probed with
indicated antibodies. b NBT-II cells were treated with HGF (5 ng/ml) and/or AZD0530 (1 μM) and lysed at the indicated time points. Whole-cell extracts
were probed with the indicated antibodies. c 293 T cells were transfected as indicated. Whole-cell extracts were probed with the indicated antibodies. TβRI
in relation to β-actin was quantified using ImageJ. d 293 T cells were transfected as indicated. Whole-cell extracts were probed with the indicated
antibodies. TβRI in relation to β-actin was quantified using ImageJ. e 293 T cells were transfected as indicated. After 48 h, cells were treated overnight with
MG132 (2 μM). Whole-cell extracts were probed with the indicated antibodies. f 293 T cells were transfected as indicated. After 48 h, cells were treated
with TGF-β (2.5 ng/ml) overnight. Whole-cell extracts were probed with the indicated antibodies. g 293 T cells were transfected as indicated. Whole-cell
extracts were probed with the indicated antibodies. h 293 T cells were transfected as indicated. Whole-cell extracts were probed with the indicated
antibodies. i Schematic of HGF-induced TGFβ activation and corresponding downregulation of MAPK pathway
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Fig. 7 HGF-induced invasion is abrogated by TβR inhibition. a EMT scores of TCGA Bladder Cancer data set (BLCA n= 408) compared with HGF
expression (left panel; R= 0.683, p= 2.3E-57), phospho c-Met expression (middle panel; R= 0.3101, p= 5.19E-9) and c-Met expression (right panel; R=
0.1538, p= 0.0018). The p value is computed by Spearman correlation coefficient test. b Kaplan–Meier curves showing probability of overall survival of
bladder cancer patients with higher copy number of HGF is significantly less than those with lower level of HGF (BLCA n= 408, p= 0.0429, HR= 1.562).
The p value is computed by log-rank test. c EMT scores of 21 bladder cancer cell lines defined as either epithelial (green) or mesenchymal (red).
d, e Analysis of bladder tumours formed from intraluminally implanted UMUC3 cells in the absence or presence of TβR inhibitors. Treatment was started
when bioluminescence intensity reached ~ 5e8 photons/sec. Mice were treated for 2 weeks and tumour volumes were measured twice a week. M=
muscularis propria. d H&E staining of representative tumour samples. Daily administration of vehicle control only (control; n= 5) or A83-01 (50mg/kg;
n= 5). T-stages at end of experiment in control-treated mice indicated T3-3 mice, T2-2 mice. All A83-01 treated mice were T1. Scale bars: 4 mm. e H&E
staining of representative tumour samples. Daily administration of vehicle control only (control; n= 3) or LY2157299 (80mg/kg; n= 3). T-stages at end of
experiment indicated T3-1 mice, T1-2 mice. All LY2157299 treated mice were T1. Scale bars: 50mm
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signalling. Furthermore, it would be predicted that loss of MAPK
signalling would induce TβR activation. To this end, we treated
both UMUC3 and T24 cells with either LY2157299 or
PD0325901, or the combination, and interrogated the invasion
capacity of both cell lines. Treatment with the TGFβ inhibitor
LY2157299 diminished the invasion capacity of both cell lines
(Fig. 8a, c). In contrast, PD0325901 partially enhanced the
invasion capacity of both cell lines potentially owing to the
activation of compensatory mechanisms, resulting in the activa-
tion of TGFβ signalling. However, dual inhibition of both TGFβ
and MAPK signalling nearly completely abolished the invasion
capacity of these cell lines (Fig. 8a–d). Next, we sought to
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determine whether the dual inhibition of MAPK and TGFβ sig-
nalling correlated with diminished anchorage-independent
growth. Although both LY2157299 and PD0325901 were effec-
tive at reducing growth in soft agar of UMUC3 cells, combina-
torial treatment significantly inhibited colony forming ability
compared with either compound alone (Fig. 8e). Similar effects
were observed using A83-01 and PD0325901 (Supplementary
Fig. 15). To further assess the cross-activation of TGFβ and
MAPK signalling with MEK and TβR inhibitors, respectively, we
treated T24 cells with either LY2157299 or PD0325901 or the
combination in the presence of HGF and observed the inter-
cellular responses. Consistent with our previous results, treatment
of T24 cells with the MEK inhibitor PD0325901 upregulated
pSMAD2C, whereas treatment with the TβR inhibitor LY2157299
enhanced pERK levels (Fig. 8f). Importantly, treatment with the
combination of LY2157299 and PD0325901 completely abolished
pSMAD2C and pERK levels (Fig. 8f).
As most bladder cancers eventually invade the surrounding
smooth muscle, we sought to generate an orthotopic bladder
cancer model by injecting bladder cancer cells intramurally to
gain insight into the potential anti-tumour invasive activity of
MEK and TβR inhibition in vivo. T24 cells were generated to
stably express a mammalian codon-optimised firefly luciferase2
permitting bioluminescence detection. Following tumour forma-
tion, mice were paired and treated by oral gavage with either
vehicle or LY2157299 or PD0325901 or a combination of the two.
Similar to our previous observations using our intravesical
inoculation model, the addition of LY2157299 decreased tumour
size and inhibited the invasion of established tumours through
the submucosa and muscular layers, however, as before,
remaining tumours maintained a high level of proliferative
capacity (Fig. 8g–i). In contrast, although MEK inhibitor treated
tumours decreased in overall size, tumour invasion remained
equivalent to control-treated tumours (Fig. 8g–i). Treatment with
the combination MEK and TβR inhibition not only abrogated
tumour cell invasion but the remaining tumour size was
decreased compared with treatment with either inhibitor alone
(Fig. 8g–i). Furthermore, in vivo pharmacodynamics assessment
shows that treatment with PD0325901 enhances pSMAD2,
whereas treatment with LY2157299 enhances pERK an effect,
which is circumvented when mice are treated with the
combination (Fig. 8j). These set of experiments confirm that
the combination of both drugs is required to effectively inhibit
invasion and proliferation.
Discussion
The invasive potential of carcinoma cells is determined by a
multitude of factors, including the ability of cells to undergo
EMT. Furthermore, it has now become apparently clear that the
surrounding tumour microenvironment can promote pro-
invasive phenotypes. The recent observation that EMT occurs
primarily within the invasive front of the tumour underlies the
role of the microenvironment in this setting12–14. HGF/c-MET
signalling has been shown to promote tumour progression, par-
ticularly influencing tumour invasiveness and metastatic
potential52,53. HGF and soluble Met levels are highly expressed in
the serum of bladder cancer patients, positively correlating with
disease progression16,54. Although some multi-kinase inhibitors
that target Met have received regulatory approval for the treat-
ment of bladder cancer overall survival rates in MIBC remain
relatively unchanged. The goal of the present study was to
identify the mechanism underlying the function of HGF/c-Met in
bladder tumourigenesis.
Recently, we performed a meta-analysis of 2411 bladder cancer
patients, allowing to identify six major molecular subtypes
including two molecular subtypes, MES and SCC, which exhibit
high EMT score51. To further understand the role of EMT in
bladder cancer we utilised an in vitro-based model, which can
undergo EMT in short-term cultures and compared real-time
changes in cell plasticity with transcriptomics following HGF
treatment. This allowed a comparison between gene expression in
cells undergoing phenotypic EMT. HGF treatment and con-
comitant c-Met activation results in the activation of a number of
downstream pathways including PI3K, RAC/PAK, MAPK, etc.
We also observe a rapid upregulation of pERK following HGF
stimulation. Interestingly, sustained pERK was not observed with
phosphorylation levels, declining over time until baseline pERK
levels were reached. Accompanying the decline in pERK, we
observed an increase in p-c-SRC, and pSMAD2L pSMAD2C. The
central dogma suggests that pSMAD2C can only occur down-
stream of TGFβ-like receptors, indicating that HGF may stimu-
late TβR activity. Accordingly, inhibition of TGFβ pathway
activation using either the TβR kinase inhibitors or knockdown of
SMAD2 inhibited HGF-induced scattering and loss of EMT
marker expression, suggesting that TGFβ activity is critical for
HGF-induced EMT and invasion. Furthermore, transcriptomic
analysis revealed that HGF treatment induces a subset of genes
corresponding to known TGFβ and EMT signatures.
In advanced cancers, TGFβ functions as an oncogenic factor
enhancing proliferation, invasion and metastasis55,56. Our study
reveals that HGF/c-MET requires a functional TβR signalling
component for this to occur. Recently, it has been demonstrated
that TGFβ family ligands correlate with a more aggressive phe-
notype in bladder cancer cell lines and deregulated TGFβ sig-
nalling leads to enhanced migration and invasiveness of bladder
cancer cells57. We demonstrate that in orthotopic mouse models,
inhibition of TβR signalling completely reverses the invasion
capacity of the bladder cancer cell line UMUC3. However, we
Fig. 8 HGF-induced invasion and proliferation is abrogated by TβR/MEK inhibition. a Transwell assay of UMUC3 cells treated with LY2157299 (1 μM) or
PD0325901 (1 μM) or the combination for 16 h prior to fixation and crystal violet staining. Scale bars: 100 μm. b Graph represents average number of
migrated cells taken from four different random fields from panel. Data are mean ± SD of triplicate samples from a representative experiment performed
three times. Student’s t test compares the treated populations, *P < 0.05, ***P < 0.001. c Transwell assay of T24 cells treated with LY2157299 (1 μM) or
PD0325901 (1 μM) or the combination for 16 h prior to fixation and crystal violet staining. d Graph represents average number of migrated cells taken from
four different random fields from panel. Data are mean ± SD of triplicate samples from a representative experiment performed three times. Student’s t test
compares the treated populations, **P < 0.01, ***P < 0.001. e Soft agar growth assay of UMUC3 cells treated with either LY2157299, PD0325901 or both.
f Western blot analysis of T24 cells treated with 5 ng/ml of HGF in the presence or absence of LY2157299 (1 μM), PD0325901 (1 μM) or both. Lysates
were collected at denoted time points and probed with indicated antibodies. pSMAD2C in relation to total SMAD2 and pERK in relation to total ERK was
quantified using ImageJ. g Bioluminescent images of mice injected luciferase tagged T24 cells intramurally in the bladder. Daily administration of vehicle
control only (control), PD0325901 (25mg/kg), LY2157299 (80mg/kg) or the combination started when bioluminescence intensity reaches ~ 2e8
photons/sec. Bioluminescence was measured once a week (n= 5/treatment group). Scale bars= p/sec/cm2/sr. h Quantitative analysis of bioluminescent
signal intensity over days after injection. ***P value < 0.001. i H&E staining of representative tumour samples from g. Scale bars: 4 mm. j Tumours
generated in g were analysed by IHC for pSMAD2 and pERK. Representative images are displayed. Original magnification × 400. Scale bars: 50 μm
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noted that loss of TβR signalling had modest impact on tumour
regression. Further in vitro and in vivo analysis revealed a cross-
talk between MAPK and TβR signalling, whereby inhibition of
either MAPK or TGFβ would result in hyperactivation of the
other. Importantly, combined inhibition of both MAPK and TβR
resulted in a decrease in both clonogenic capacity and invasive
growth capability. For these reasons, we favour the initial clinical
development of this combination in bladder cancer patients with
aggressive T1 tumours.
The primary function of c-SRC is to couple receptor activation
with the cytoplasmic signalling machinery, thereby regulating a
number of fundamental cellular processes. c-SRC has long been
shown to be positive regulator of EMT but the mechanistic
actions of c-SRC in this setting remain vague35. To prevent
uncontrolled ubiquitination of its substrates, SMURF2 ligase
activity is obstructed through the formation of intramolecular
interactions between the C2 and HECT domains32. The C2-
HECT formation is antagonised upon the binding of SMAD7,
resulting in the activation of SMURF2 and ubiquitination of
SMURF2 substrates including the TβR complex and β-TrCP28,49.
β-TrCP targets K-RAS for proteasome-mediated degradation.
The net result of SMURF2 activation is downregulation of TGFβ
signalling and concomitant upregulation of MAPK activity
through the stabilisation of K-RAS. We show that HGF induces c-
SRC tyrosine phosphorylation of SMURF2 at Tyr314 and Tyr434,
resulting in the inhibition of SMAD7 binding and enhancement
of electrostatic interactions between the HECT domain and C2
domain, respectively, resulting in downregulation of SMURF2
ligase activity. There are a number of direct implications to these
results. First, SMURF2 inhibition by c-SRC upregulates the TβR
pathway by stabilising TGFβR complex a function we define to be
critical for HGF-induced EMT and invasion in vitro and tumour
progression in vivo in bladder cancer. Second, the observation
that c-SRC phosphorylation of SMURF2 results in the down-
regulation of MAPK activity reveals the identification of a novel
adaptive response mediated by a c-SRC-SMURF2 axis to down-
regulate MAPK signalling following HGF stimulation. This is
unsurprising as a number of negative feedback loops have already
been identified, which regulate this kinase cascade58–60. Taken
together, our results indicate that HGF induces c-SRC-mediated
phosphorylation of SMURF2 whereby SMURF2 acts as a tem-
poral bimodal switch between MAPK and TGFβ signalling. This
places SMURF2 at a key node in the regulation of either a pro-
proliferative or invasive phenotypes.
As c-SRC is activated downstream by a number of RTKs, it
would be unsurprising if loss of c-SRC activity by EGFR, HER2 or
FGFR inhibitors would not have a deleterious effect on down-
regulation of the MAPK pathway as SMURF2 would remain
active and as a consequence K-RAS would remain stable. It has
recently been shown that EGFR activation results in c-SRC-
mediated phosphorylation of NEDD4, suggesting that a similar
outcome may occur with SMURF2. Therefore, future clinical
studies may be required to incorporate MEK inhibitors with
either EGFR, FGFR or HER2 inhibitors in relevant patient set-
tings to observe complete downregulation of MAPK signalling.
Furthermore, our observations suggest that c-SRC inhibitor
monotherapy may function to prevent invasion and metastasis in
high-grade T1 stage bladder cancers particularly in BCG refrac-
tory patients. In summary our findings suggest that TβR activa-
tion is a critical factor in c-MET induced bladder cancer invasion
and further studies into the potential use of TβR and MAPK
inhibitors is warranted.
Methods
Cell lines and culture conditions. The transitional carcinoma cell lines NBT-II,
T24, J82, UMUC3 and human embryonic kidney cells HEK293T were obtained
from the American Type Culture Collection (ATCC; catalogue no. CRL-1655 and
CRL-1749). Cells were routinely cultured in Dulbecco’s modified eagle medium
(DMEM, Gibco, Life Technologies) supplemented with 10% fetal bovine serum
(FBS, HyClone Thermo Scientific), and 100 units/ml penicillin–streptomycin (1 ×
pen–strep, Invitrogen). Cultured cells were regularly tested for mycoplasma con-
tamination. Cells were grown in a 5% CO2 atmosphere incubator at 37 °C. When
appropriate HGF (5 ng/ml, Calbiochem), TGF-β1 (2.5 ng/ml, R&D), SB431542
(5 μM, Tocris), A83-01 (8 μM, Tocris), A83-01 is a small molecule inhibitor spe-
cifically targeting TβRI (ALK5), Activin receptor type-1B/ALK4 and Activin
receptor type-A/ALK-7, the three of which contain highly structurally related
kinase domains, PD0325901 (1 μM, Selleck Chemicals), LY2157299 (1 μM, Selleck
Chemicals), AZD0530 (2 µM, Selleck Chemicals), JNJ38877605 (4 µM, Selleck
Chemicals) or MG132 (2 μM; Sigma) was added. All cell lines were independently
genotyped and validated (please refer to source data).
EMT inhibition and cell tracking. EMT induction with HGF and inhibitory effects
of selected compounds were validated by NBT-II epithelial colony time-lapse
microscopy. NBT-II cells were plated onto 12-well plate (BD) at a low density of
200 cells per well in 2 ml of medium. Cells were allowed to grow and form epi-
thelial colonies for a period of 4 days. The cultures were then refreshed with
medium containing with or without 5 ng/ml HGF or compound 2 µM AZD0530
(Selleck Chemicals) prior to time-lapse imaging. Time-lapse microscopy of indi-
vidual cell colonies was performed using a video microscope incubator system
(Axiovert-200M, Carl Zeiss). Time-lapse images were taken at 5 min intervals for
24 h. Tracking of cells was performed with the particle tracking function in
Metamorph software (Metamorph).
Transient transfection. HEK293T cells were transfected using calcium chloride
and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered saline
(pH 6.95). Sixteen hours after transfection, cells were washed twice with 1 ×
phosphate-buffered saline (PBS) and replenished with fresh media. The cells were
grown for a further 24 h before processing for cell lysis. UMUC3 cells were
transfected using lipofectamine 3000 according to manufacturer’s protocol.
Stable transfection. NBT-II were transiently transfected with a plasmid har-
bouring a kinase-dead mutation K295R or constitutive active mutation Y527F in c-
SRC or kinase-dead TGFβR I using lipofectamine 3000, according to manu-
facturer’s protocol (Invitrogen). UMUC3 were stably transfected with a plasmid
harbouring either dominant negative SMAD2 having point mutation S/T phos-
phorylation sites in the linker region (T220V, S245A, S250A, S255A) or deletion of
four amino acids at the carboxyl terminal region (deposited by Rik Derynck;
Addgene plasmid 12637) followed by selection for single clones by supplementing
1 µg/ml puromycin (Invitrogen) to the media. pLNCX chick c-SRC K295R was a
gift from Joan Brugge (Addgene plasmid # 13659); pLNCX chick c-SRC Y527F was
a gift from Joan Brugge (Addgene plasmid # 13660); pCMV5B-TGF-beta receptor I
K232R was a gift from Jeff Wrana (Addgene plasmid # 11763); pCMV5 Flag-
SMAD2 EPSM was a gift from Joan Massague (Addgene plasmid # 14933); LPCX
SMAD2 deltaSSMS was a gift from Rik Derynck (Addgene plasmid # 12637).
Immunofluorescence. NBT-II cells were seeded at a density of 100 cells per well
on Ibidi eight-well μ-slides and grown for 4 days to form colonies. Cells were pre-
treated with 5 ng/ml of HGF (Calbiochem) and then fixed with 4% paraf-
ormaldehyde and stained with mouse anti-rat Desmoplakin (clone DP2.15, Mil-
lipore), mouse anti-human E-cadherin (clone 36/E-cadherin (RUO), BD), mouse
anti-human Vimentin (clone V9, Abcam) and mouse anti-Smad2/3 (clone
18Smad2/3, BD) primary antibodies. A goat anti-mouse antibody conjugated to
Alexa Fluor 488 (Invitrogen) was used as a secondary antibody. Fluorescent images
were captured with a Leica DM6000b inverted microscope (Leica Microsystems)
and monochrome coolsnap HQ2 camera (Photometrix).
Immunohistochemistry. Immunohistochemistry was performed by AMPL
A*STAR. In brief, samples are paraformaldehyde fixed and paraffin embedded, cut
on microtome (6 µm thickness) and deparaffinised, rehydrated and heated in
Antigen Retrieval Citrate Solution, pH 6 (Abcam) before staining. Sections were
incubated with Dual Endogenous Enzyme Block (Dako, Glostrup, Denmark), and
were treated with Protein Block Serum-Free (Dako). Slides were incubated at room
temperature for 1 h with rabbit monoclonal anti-human pERK (T202/Y204)
antibody (clone D13.14.4E, dilution 1:400), rabbit monoclonal anti-human pSmad2
(S465/467) antibody (clone 138D4, dilution 1:50), rabbit monoclonal anti-human
pSmad2 (S245/250/255) antibody (CST #3104, dilution 1:50) and rabbit mono-
clonal anti-human pSrc (Y416) antibody (clone D49G4, dilution 1:100) (followed
by DAB substrate kit (Abcam) and counterstained with hematoxylin. Slides were
scanned with Amperio slide scanner (Leica) and analysed by pathologists at AMPL
and at the Hopital Foch (Paris, France). Declaration Number for the cohort of
Bladder Cancer tissue samples used in this study No. DC-2017-2942 ministry of
research, division of bioethics, Head of Project Rouanne Mathieu.
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Phospho-specific protein microarray analysis. NBT-II cells were seeded at a
density of 0.5 × 106 cells per 10 cm cell culture-treated dish (NUNC) and grown for
4 days to form colonies. Cells were either treated with or without 5 ng/mL of HGF
(Calbiochem) for 2 hours before harvesting. Cells were harvested by incubating
cells with dissociation buffer (Gibco) for 10 min and centrifuged at 300 × g for 5
min. Cell pellets were snap frozen with liquid nitrogen and sent to Fullmoon
Biosystems (Sunnyvale, CA, USA) for processing, hybridisation and phospho-array
detection of the TGF-β Signalling Phospho-Specific Antibody Array (Fullmoon
Biosystems, Sunnyvale, CA, USA). Fluorescence intensity was scanned with an
Axon GenePix 4400 A microarray scanner (Axon, Sunnyvale, CA, USA) at 760 nm
wavelength. Each slide was analysed by the software GenePix Pro 7126 and
phosphorylation ratio was calculated from the raw data with phospho value/
unphospho-value (provided by Fullmoon Biosystems).
Microarray data analysis. HGF-treated NBT-II bladder carcinoma cells at 0, 2, 4,
6, 9, 24, 48 h were subjected to microarray gene expression profiling on Affymetrix
Rat Gene 1.0 ST platform. The data had been deposited in Gene Expression
Omnibus (GEO) with the accession GSE104740. The preprocessing of microarray
was performed using Partek software version 5.0 (Partek Incorporated). Probeset
intensities were normalised using RMA algorithm. Log2 probe intensities of below
6 were deemed low expression and were filtered off from the analysis. Significant
differentially expressed genes were chosen with criteria of FDR 0.01 and a mini-
mum fold change of 1.2.
Mass spectrometry analysis. Samples were treated by in-gel digestion prior to
MS analysis. In brief, samples were reduced in 10 mM dithiothreitol (DTT) for 1 h
at 56 °C followed by alkylation with 55 mM iodoacetamide (Sigma) for 45 min in
the dark. Tryptic digest was performed overnight in 50 mM ammonium bicarbo-
nate buffer with 2 μg trypsin (Promega) at 37 °C. Peptides were desalted on
StageTips and analysed by nanoflow liquid chromatography on an EASY-nLC
1200 system coupled to a Q Exactive HF mass spectrometer (Thermo Fisher Sci-
entific). Peptides were separated on a C18-reversed phase column (25 cm long, 75-
μm inner diameter) packed in-house with ReproSil-Pur C18-QAQ 1.9-μm resin.
The column was mounted on an Easy Flex Nano Source and temperature con-
trolled by a column oven (Sonation) at 40 °C. A 105-min gradient from 2 to 40%
acetonitrile in 0.5% formic acid at a flow of 225 nl/min was used. Spray voltage was
set to 2.4 kV. The Q Exactive HF was operated with a TOP20 MS/MS spectra
acquisition method per MS full scan. MS scans were conducted with 60,000 and
MS/MS scans with 15,000 resolution. The raw files were processed with MaxQuant
version 1.5.2.8 with preset standard settings for SILAC labelled samples and the re-
quantify option was activated61. Carbamidomethylation was set as fixed mod-
ification while methionine oxidation, protein N-acetylation and phosphorylation
(STY) were considered as variable modifications. Search results were filtered with a
false discovery rate of 0.01.
Statistical analysis. Pathway enrichment analyses were performed using signature
from Molecular signature database (Msigdb v5.0) and ssGSEA projection method
implemented in R 3.3.1 bioconductor package GSVA 1.20.0. P value is computed
by two-tailed unpaired t test.
Nuclear cytoplasmic fractionation assay. NBT-II cells were seeded at a density of
0.5 × 106 cells per 10 cm cell culture-treated dish (NUNC) and grown for 4 days to
form colonies. Cells were pre-treated with 5 ng/ml of HGF (Calbiochem) alone or
HGF with 8 µM A83-01 (Tocris Bioscience) before harvesting. Cells were trypsi-
nized and the number of cells in each sample was quantified. Equal number of cells
was pelleted for each sample. Fractionation was performed using Qproteome cell
compartment kit (Qiagen), according to manufacturer’s protocol.
Site directed mutagenesis. These PCR reactions were performed using Quik-
Change XL kit by Agilent Technologies (catalogue no. 200517-4) according to
manufacturer’s instructions. The presence of mutants was confirmed by Sanger
sequencing.
Modelling the HECT: C2 domain complex of SMURF2. The NMR structure of
the C2 domain (PDB ID: 2JQZ) and the X-ray crystal structure of the HECT
domain (PDB ID: 1ZVD) of SMURF2 protein were downloaded from the Protein
Data Bank29,32. The lowest energy state model (Model 1) from the ensemble of
C2 structures was selected for the study. The effective length considered for the C2
domain was 131 residues (10–140) and for the HECT domain was 371 residues
(369–739), residue numbering as per Uniprot ID: Q9HAU4. These two indepen-
dently solved structures of C2 and HECT (Fig. S7A, B) were used to model the
HECT-C2 domain complex using the programme HADDOCK through its web
portal62. The work by Mari et al. and Wiesner et al.32,63 where they have mapped
the potential binding interface and residues involved in interaction between the
HECT and C2 domains of SMURF2, were used as references to specifically define
the active (F403, E407, Y454 for HECT; F29, F30, R31, L57 for C2) and passive site
residues (R399, E401, I402, M409, Y453, Y482, I489, E666, Q673, S678 for HECT;
K27, L32, T56, K84, H86, K88 for C2) for docking. A total of 10 structure clusters
were generated after docking of the two domains. The representative structure
from the top cluster with the best score as computed by the scoring scheme used in
HADDOCK was selected as an initial model (Fig. S7C). It has also been previously
suggested by Wiesner et al.32 that the C-lobe in HECT could rotate around the
well-known flexible linker connecting the N- and C-lobes in order to facilitate a
more favourable conformation of the two lobes for C2 interaction as compared
with the state observed in the crystal structure of HECT (PDB ID: 1ZVD). So, as a
further optimisation to our initial docked model, the C-lobe was rotated around the
linker (628GLGKID632) by gradually changing their backbone dihedral angles in
steps. This was done till the region from C-lobe, which has the residues predicted
to be involved in interaction with C2 was in close proximity to the docked C2
domain (Fig. S7D). Subsequently, the complex structure was refined by energy
minimisation to obtain the final representative docked HECT-C2 complex state
structure of Smurf2 (Fig. S7E).
System setup for molecular dynamics simulations. The NMR structure of
SMURF2 WW3 domain in complex with a SMAD7-derived peptide (PDB ID:
2LTZ) was downloaded from the Protein Data Bank47. The lowest energy state
model (Model 1) from the ensemble of structures was selected for simulation. The
effective length for WW3 domain was 37 residues (297–333, residue numbering as
per Uniprot ID: Q9HAU4) and for the SMAD7 peptide was 15 residues (203–217,
residue numbering as per Uniprot ID: O15105). The refined HECT-C2 complex
state obtained from docking (Fig. S7E) was used as a starting state for simulation of
this system. The phosphorylated state of Y314 in WW3-SMAD7 complex and
Y434 in HECT-C2 complex was respectively modelled in these structures which
collectively resulted in a total of four systems for simulation. The N- and C-
terminal of the separate chains in all the complexes was capped with ACE and
NME functional groups. The complexes were then placed in a cuboid box whose
dimensions were set by ensuring a minimum distance of 8 Å between any solute
atom and the edge of the box. TIP3P water model was used for solvation, and all
the systems were neutralised by adding an appropriate number of counter ions
using the TLEAP module of AMBER1464,65.
Molecular dynamics simulations. MD simulations were performed in AMBER14
using PMEMD module and employing the all-atom ff99SB force field66. The amber
library files for Phosphotyrosine were downloaded from http://research.bmh.
manchester.ac.uk/bryce/amber wherein the force field parameters for the modified
amino acid were derived from the work by Craft and Legge67. Each of the four
solvated systems were energy minimised using the steepest descent and conjugate
gradient algorithms, heated to a temperature of 300 K over 30 ps in NVT ensemble,
equilibrated for another 500 ps and finally subjected to the production run for 20
ns. Both the equilibration and production simulations were done in NPT ensemble.
In the simulation of HECT-C2 complexes, harmonic positional restrain of 5 Kcal/
mol was applied to all the backbone (N, CA, C and O) heavy atoms. Langevin
dynamics with a collision frequency of 1.0 ps−1 were used for temperature reg-
ulation and a weak-coupling with relaxation time of 1 ps was employed to maintain
the pressure at 1 atm68–70. Periodic boundary condition was appropriately applied,
and the Particle Mesh Ewald (PME) method was used for calculating long-range
electrostatic interactions71. All bonds involving hydrogen atoms were constrained
using the SHAKE algorithm with an integration time-step of 2 fs72.
Western blots and antibodies. Cells were lysed with radioimmunoprecipitation
assay (RIPA) buffer supplemented with Complete Protease inhibitor cocktail
(Roche) (RIPA: 50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM sodium orthovanadate,
50 mM sodium fluoride, 100 mM β-glycero phosphate)31. Whole cell extracts were
then separated on 7–12% SDS–PAGE (polyacrylamide gel electrophoresis) gels and
transferred to 0.45 µM PVDF membranes (Millipore). Membranes were blocked
with bovine serum albumin for all antibodies except phospho-SMAD2, which was
blocked in milk and probed with specific antibodies at 4 °C overnight. Blots were
then incubated with a horseradish peroxidase-linked second antibody and detected
using chemiluminescence (Pierce). The following antibodies were used; anti-E-
cadherin (BD), anti-FLAG and anti-α-tubulin (Sigma), anti-HA (Y11, Santa Cruz
biotech), anti-Myc (9E10 or A14, Santa Cruz Biotech), anti-phospho-SMAD2
(S465/467, Cell Signaling), anti-Laminin-b1 (Abcam), anti-SMAD2 (L16D3, Cell
Signaling), anti-β-actin (Sigma), anti-TGF-β receptor I (V-22, Santa Cruz Biotech),
anti-phospho-tyrosine (clone 4G10, Millipore, 05–321), anti-Phospho-Src (Tyr
416, 2101 S, Cell Signaling), anti-c-Src (B-12, Santa Cruz Biotech), anti-phospho-
ERK (P-p44/42 MAPK T202/Y204, 9101, Cell Signaling), anti-Total ERK (p44/42
MAPK, 9102, Cell Signaling), anti-p38 (Cell Signaling), p-c-MET Tyr1234/1235
(Cell Signaling) and anti-phospho-SMAD2 (S245/250/255, 3104, Cell Signaling).
All antibodies were used at a dilution of 1:1000. The pan TGFβ neutralising
antibody (ID11) was purchased from Genzyme, the activin ligand trap soluble
ACVR2B-Fc was a kind gift from Olli Ritvos (University of Helsinki, Finland).
Generation of phospho-specific antibodies. Phospho-specific antibodies to
Tyr314 and Tyr434 of SMURF2 were generated by Biomatik, USA. Rabbit poly-
clonal antibodies were raised against specific peptide sequences. For Tyr314,
peptide sequence corresponding to CEIRNTATGRV(pY)FVDHN was used to raise
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antibodies against the phosphorylated form and CEIRNTATGRVYFVDHN for the
unphosphorylated form. Similarly, for Tyr434, peptide sequence corresponding to
CLWKRLMIKFRGEEGLD(pY)GGVAR was used to raise antibodies against the
phosphorylated form and CLWKRLMIKFRGEEGLDYGGVAR for the unpho-
sphorylated form. The antibodies were received in lyophilised form, which was
further dissolved using in ddH2O, except antibodies for the unphosphorylated
Tyr434, which could only be dissolved in 10% DMSO. All antibodies were used at a
dilution of 1:1000.
Immunoprecipitation and In vivo deubiquitination assay. For co-
immunoprecipitation experiments, cells were lysed in ELB (250 mM NaCl, 0.5%
NP-40, 50 mM HEPES, pH 7.3) supplemented with protease inhibitors. Cell lysates
were incubated for overnight with the indicated antibodies, then conjugated to
protein A or protein G sepharose beads (GE Healthcare), washed three times in
ELB buffer, boiled in sample buffer and separated out on SDS–PAGE gels. When
appropriate cell lysates were immunoprecipitated with ANTI-FLAG M2 affinity
resin (Sigma). Wild-type Myc-tagged SMURF2 (5 μg) or corresponding relevant
mutants were co-transfected with HA-ubiquitin (3 μg). After 72 h MG132 (2 μM)
was added, incubated overnight and cells were lysed in ELB buffer. SMURF2 was
immunoprecipitated with Myc antibodies and bound proteins were resolved by
SDS–PAGE gel for further processing by immunoblotting73.
Biotin labelling of TGF-β receptor. Cell surface biotinylation was performed
using Pierce Cell surface protein isolation kit (catalogue no. 89881) according to
the manufacturer’s instructions. NBT-II cells were grown on 15 cm plates treated
with HGF (5 ng/ml), media was removed at the indicated time points and cells
were biotinylated at 4 °C for 30 min. Thereafter, cells were lysed, protein estimation
was performed and equal amounts of lysates were incubated with neutravidin
beads (from above kit) for 1 h. The beads were subsequently washed and boiled in
sample buffer with 50 mM DTT and loaded onto an SDS–PAGE gel for further
processing by immunoblotting.
Subcutaneous model. Xenografts were generated by injecting 0.1 ml of 2.5 × 106 of
UMUC3 (wild-type or transfected with either Smad2dnL or Smad2 dnC construct)
cells subcutaneously into the dorsal flanks of female BALB/c nude mice (6–8 weeks
old). Animal body weight and physical signs were monitored during the experi-
ments. Tumour size was measured weekly by Vernier calliper. The tumour volume
was calculated, with the formula: (length × width2)/2. In vivo xenograft models, the
mice were gavaged with either 50 mg/kg of A83-01 or 12.5 mg/kg of PD0325901 or
a combination of 50 mg/kg of A83-01 and 12.5 mg/kg of PD0325901 daily when
tumours reached 50 mm3.
Mouse orthotopic bladder cancer model. All animal work adhered to the Agency
of Science Technology and Research (A*STAR), Institutional Animal Care and use
Committee (IACUC), guidelines on animal use and handling. Six to eight weeks
old-female balb/c nude (nu/nu) mice were used. General anaesthesia was induced
in the mice with inhaled isoflurane and maintained via nosecone (4% for induction,
1–2% for maintenance). Sterile ophthalmic ointment was applied to the animal’s
eyes and a heating platform was used to maintain body heat. The urine of mice was
removed by applying gentle pressure on the bladder. Using a lubricated 24-gauge
intravenous catheter (Braun) connected to a 1 ml syringe (BD) with the needle
stylet removed, the mouse urethra was catherised. For bladder instillation: 100 μl of
PBS (GIBCO) was instilled into the bladder and removed to wash the lumen. In
total, 100 μl 0.25% trypsin (Sigma) was instilled in the lumen for a maximum of 30
min followed by three PBS washes. Subsequently, 100 μl of 5 × 106 UMUC3 cells
stably transfected with pGL4.51 luciferase 2/CMV vector (Promega) using Lipo-
fectamine 2000 (Invitrogen) and selected by 1 mg/ml neomycin (Sigma) were
instilled into the bladder and the catheter and syringe left in place for 3 h. For the
first experiment (A83-01) 50 mice were inoculated with 10 mice forming tumours.
Mice were then separated into vehicle control (n= 5) or treated with A83-01 (n=
5) in gavage solution (DMSO:Saline, 3:2, v/v) (80 mg/kg daily for 2 weeks).
Similarly, in the second experiment (LY2157299) 45 mice were inoculated with six
mice forming tumours. Mice were then separated into vehicle control (n= 3) or
treated with LY2157299 (n= 3) in gavage solution (0.5% hydroxyl propylnmethyl-
cellulose+ 0.2% Tween 80) (80 mg/kg daily for two weeks). For bladder wall
injection: 0.5 cm slit was made on the abdomen of mice under anaesthesia to
expose the bladder. The mice were catherised with PBS to maintain the bladder at
about 85% full. In all, 10 μl of 1 × 106 T24-luc2 cells prepared as described for
UMUC3 were injected into the bladder wall using a 31-gauge insulin syringe (BD)
under stereoscope (Leica) with × 3.5 magnification and the slit was sutured after
procedure. Tumour implantation was assessed by bioluminescence imaging with
IVIS Spectrum Imaging System 200 (Xenogen). Imaging was performed 10 min
after an intraperitoneal injection of 150 mg/kg firefly D-Luciferin in 200 μl of
PBS. Signal intensity was quantified in photons per second per region of interest.
Respective drugs were administered when bioluminescence intensity reached ~2e8
photons/sec. A83-01 administered in gavage solution (DMSO: Saline, 3:2, v/v)
(80 mg/kg daily for two weeks). LY2157299 administered in gavage solution (0.5%
hydroxyl propyl methyl-cellulose+ 0.2% Tween 80) (80 mg/kg daily for 2 weeks).
PD0325901 administered in gavage solution (1% polysorbate 80) (25 mg/kg daily
for 2 weeks).
Transwell migration assay. For transwell migration assay, UMUC3 cells or T24
cells were grown in 10 cm dishes to 80% confluency and serum-starved for 24 h. In
all, 5 × 105 cells were suspended in 1% FBS supplemented DMEM in the absence or
presence of JNJ38877605 and seeded on the upper chambers. The lower chambers
were filled with 5% FBS supplemented DMEM in the presence or absence of HGF.
Migrated cells were stained after 16 h. The cells were fixed in ice-cold methanol for
10 min and stained with crystal violet solution. The inner side of the upper
chamber was wiped with cotton swabs. Migrated cells were then visualised through
brightfield microscope and pictures were taken at four random sites and quantified.
Soft agar. The soft agar assay consisted of three layers. 0.6 mL bottom layer of
0.6% agar in 10% supplemented DMEM was dispensed into each well of a 24-well
plate and allowed to solidify at room temperature for half hour. UMUC3 cells with
or without transient transfection were trypsinized and counted. 0.5 mL middle
layer of 0.36% agar and 5 × 105 UMUC3 carcinoma cells in 10% supplemented
RPMI was plated above the bottom layer and allowed to solidify at room tem-
perature for half hour. The top layer consisted of 0.5 mL/well of 10% FBS sup-
plemented DMEM in the presence or absence of small molecular weight
compounds and incubated at 37 °C in a humidified incubator with 5% CO2 for
2 weeks and stained with MTT (Abcam). The plates were scanned and images from
three replicates were quantified.
Luciferase assays. Luciferase assays were performed using the Dual luciferase
system (Promega). CAGA-luciferase vector (300 ng) was transfected in the pre-
sence of SMURF2 (1 μg) or relevant mutants, and CMV-Renilla (0.25 μg). After
72 h TGF-β1 (2.5 ng/ml) was added in DMEM (0% FCS) and luciferase counts
were measured 12 h later using a Sirius Luminometer (Berthold).
RT2 profiler. The expression profile of 84 TGFβ pathway-related genes was
determined using a 96-well format TGFβ signalling pathway RT2 Profiler PCR
array (Qiagen-PARN-035) according to the manufacturer’s instructions. The array
also included six housekeeping genes and three RNA as internal controls. qPCR
were run on an ABI 7900HT qPCR instrument (Applied Biosystems, UK) equipped
with SDS 2.3 software, using RT2 SYBR Green/ROX qPCR master mix. Data
analysis was done by the 2−ΔΔCt method on the manufacturer’s Web portal. http://
pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php.
Quantitative real-time PCR. Cells were collected, washed twice in PBS and RNA
was isolated using GeneJet RNA extraction kit (Thermo Scientific) qRT was per-
formed using Taqman probes (USP26) from Applied Biosystems according to
manufacturer's recommendations. Reactions were carried out on a ABI 7900 or
7500 FAST sequence detector (Perkin Elmer). Relative mRNA values are calculated
by the ΔΔCt method. GAPDH or 18 S were used as internal normalisation controls
where specified. The following QRT primers were used: PAI-1-5´-AAGG-
CACCTCTGAGAACTTCA-3´, 5´-CCCAGGACTAGGCAGGTG-3´.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The molecular dynamics simulation trajectories and the coordinates files of the molecular
models reported in the paper are available from the Figshare repository (https://figshare.
com/articles/_/9044549). The NBT-II transcriptomic data are available from the GEO
repository with the accession GSE104740. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via the PRIDE [1] partner
repository with the dataset identifier PXD014736. All other source data are available from
the corresponding authors on reasonable request and/or are included with the
manuscript (as figure source data or Supplementary Information).
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